논문 상세보기

대한간학회> Postgraduate Courses (PG)> 알코올 간질환 환자에서 고위험 환자의 선별

알코올 간질환 환자에서 고위험 환자의 선별

How to Identify High-Risk Individuals in Alcoholic Liver Disease

송도선 ( Do Seon Song )
  • : 대한간학회
  • : Postgraduate Courses (PG) 2021권1호
  • : 프로시딩
  • : 2021년 05월
  • : 57-62(6pages)
Postgraduate Courses (PG)

DOI


목차

서 론
본 론
결 론
참고문헌

키워드 보기


초록 보기

Alcoholic liver disease includes steatosis, steatohepatitis, progressive fibrosis, and cirrhosis. Alcoholic hepatitis (AH) is an acute inflammatory syndrome characterized by rapid development of jaundice and liver-related complications, and it is associated, particularly if severe, with high mortality. Several prognostic models using laboratory or histologic markers have been used to estimate short-term mortality and to identify those who may benefit from treatment. Recently, prognostic models for acute-on-chronic liver failure were used in patients with severe AH, and systemic inflammatory markers and markers for hepatic injury were also studied for identifying high risk patients. Further studies to find models which can predict prognosis more accurately are needed in the future.

UCI(KEPA)

간행물정보

  • : 의약학분야  > 내과학
  • :
  • :
  • : 연간
  • :
  • :
  • : 학술지
  • : 프로시딩
  • : 2012-2021
  • : 154


저작권 안내

한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.

이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.

2021권1호(2021년 05월) 수록논문
최근 권호 논문
| | | |

1New Indications and New Endpoints of hepatitis B Virus Treatment: When to Start, Change and Stop?

저자 : Hyung Joon Yim

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 3-4 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

2Hepatitis C Virus Simplified Algorithm for Treatment: Who Is Eligible for Simplified Treatment

저자 : In Hee Kim

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 5-18 (14 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Hepatitis C virus (HCV) treatment guidelines are comprehensive and may be most appropriate for experienced HCV specialists. A simplified treatment algorithm is suggested to provide guidance for non-HCV specialists. The simplified HCV treatment algorithm begins with universal HCV screening and diagnosis by testing for HCV antibody with reflex to polymerase chain reaction to detect HCV RNA. The pretreatment evaluation includes assessment of fibrosis/cirrhosis, potential drug-drug interactions and education of patients. The pan-genotypic regimens such as glecaprevir/pibrentasvir or sofosbuvir/velpatasvir are recommended for treatment. Unless clinically indicated, on-treatment monitoring is optional. Confirmation of cure (undetectable HCV RNA 12 weeks post-treatment) is followed by harm-reduction measures, as well as surveillance for hepatocellular carcinoma every 6 months in patients with advanced fibrosis/cirrhosis. Simplified, genotyping/subtyping-free, pan-genotypic anti-HCV treatment must be used to improve access to HCV treatment and increase the global infection cure rates in any setting where genotype and subtype determination is not available, not affordable and/or would limit access to therapy. However, in settings where HCV genotype and subtype determination are available and affordable and would not limit access to care, this information remains useful to optimise the results of anti-HCV therapy.

3동반 질환에 근거한 B형 및 C형 간염 바이러스에 대한 개별화된 치료

저자 : 진영주 ( Young-joo Jin )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 19-19 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

4A형, D형 및 E형간염 바이러스 감염의 최신지견

저자 : 이세환 ( Sae Hwan Lee )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 20-24 (5 pages)

다운로드

(기관인증 필요)

초록보기

Hepatitis A virus (HAV) is transmitted through fecal-oral infection, and acute hepatitis A infection has been continuously occurring in Korea since the 2000s. Despite ongoing medical and national health policy efforts for the prevention and treatment of acute hepatitis A, sporadic large-scale outbreaks were reported until today. Hepatitis E virus (HEV) is also transmitted by fecal-oral infection and the incidence of acute hepatitis E is not high in Korea, but it is one of the causes of acute hepatitis. In the case of hepatitis D virus (HDV) infection, there are still many limitations in diagnosis and treatment in worldwide.

5COVID-19의 역학과 SARS-CoV-2 바이러스의 특성

저자 : 최원석 ( Won-suk Choi )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 27-30 (4 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Since COVID-19 cases were reported in China in December 2019, the global COVID-19 pandemic continues. Initially, the known information about COVID-19 was very limited, but recently, various research results on epidemiological and viral characteristics have been reported. With increasing understanding of the disease, various medical and public health measures have been made and applied. In this lecture, the epidemiological characteristics of COVID-19 and the characteristics of SARS-CoV-2 that have been identified so far will be covered.

6COVID-19 상황에서 간질환 환자의 진료 가이던스

저자 : 이정훈 ( Jeong-hoon Lee )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 31-44 (14 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

7COVID-19과 간질환과의 연관

저자 : 정우진 ( Woo Jin Chung )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 45-49 (5 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Coronavirus disease 2019 (COVID-19) pandemics affected many aspects of the socioeconomic structure in Korea, especially in medical practice. As a major route of infection, the respiratory system is a key organ leading to increased risk of mortality and morbidity. However, it is well known that extra-respiratory involvement of COVID-19 also significantly affects patients' outcomes. Patients with chronic liver disease are not at increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). But, the risk of severe courses of COVID-19 may be different depending on the nature of the chronic liver disease and the presence of advanced fibrosis or cirrhosis. The present topic will summarize current evidences on the risk of infection and severe COVID-19 courses in patients with variable liver diseases.

8The Challenges and Achievements in COVID-19 Treatment and Vaccines

저자 : Pyoeng Gyun Choe

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 50-53 (4 pages)

다운로드

(기관인증 필요)

초록보기

In December 2019, a new strain of betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that cause coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Subsequently, the virus quickly spread worldwide, and the World Health Organization declared COVID-19 as a global pandemic on March 11, 2020. In response to the pandemic, many researchers are rushing to repurpose existing drugs to alter the course of severe COVID-19, as well as testing experimental treatments. Among antiviral agents, remdesivir, RNA-dependent RNA polymerase inhibitor, showed clinical benefit from randomized clinical trial. In October 2020, the FDA approved remdesivir for treating hospitalized patients with COVID-19, making it the first drug approved for COVID-19 treatment. The race to produce safe and effective vaccines is also moving at unprecedent speed. In December 2020, the FDA issued an emergency authorization use for the first vaccine for COVID-19.

9알코올 간질환 환자에서 고위험 환자의 선별

저자 : 송도선 ( Do Seon Song )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 57-62 (6 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Alcoholic liver disease includes steatosis, steatohepatitis, progressive fibrosis, and cirrhosis. Alcoholic hepatitis (AH) is an acute inflammatory syndrome characterized by rapid development of jaundice and liver-related complications, and it is associated, particularly if severe, with high mortality. Several prognostic models using laboratory or histologic markers have been used to estimate short-term mortality and to identify those who may benefit from treatment. Recently, prognostic models for acute-on-chronic liver failure were used in patients with severe AH, and systemic inflammatory markers and markers for hepatic injury were also studied for identifying high risk patients. Further studies to find models which can predict prognosis more accurately are needed in the future.

10How to Predict Rapid Progression of Fibrosis in Nonalcoholic Fatty Liver Disease

저자 : Byoung Kuk Jang

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 63-63 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기
12
권호별 보기
같은 권호 다른 논문
| | | | 다운로드

1New Indications and New Endpoints of hepatitis B Virus Treatment: When to Start, Change and Stop?

저자 : Hyung Joon Yim

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 3-4 (2 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

2Hepatitis C Virus Simplified Algorithm for Treatment: Who Is Eligible for Simplified Treatment

저자 : In Hee Kim

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 5-18 (14 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Hepatitis C virus (HCV) treatment guidelines are comprehensive and may be most appropriate for experienced HCV specialists. A simplified treatment algorithm is suggested to provide guidance for non-HCV specialists. The simplified HCV treatment algorithm begins with universal HCV screening and diagnosis by testing for HCV antibody with reflex to polymerase chain reaction to detect HCV RNA. The pretreatment evaluation includes assessment of fibrosis/cirrhosis, potential drug-drug interactions and education of patients. The pan-genotypic regimens such as glecaprevir/pibrentasvir or sofosbuvir/velpatasvir are recommended for treatment. Unless clinically indicated, on-treatment monitoring is optional. Confirmation of cure (undetectable HCV RNA 12 weeks post-treatment) is followed by harm-reduction measures, as well as surveillance for hepatocellular carcinoma every 6 months in patients with advanced fibrosis/cirrhosis. Simplified, genotyping/subtyping-free, pan-genotypic anti-HCV treatment must be used to improve access to HCV treatment and increase the global infection cure rates in any setting where genotype and subtype determination is not available, not affordable and/or would limit access to therapy. However, in settings where HCV genotype and subtype determination are available and affordable and would not limit access to care, this information remains useful to optimise the results of anti-HCV therapy.

3동반 질환에 근거한 B형 및 C형 간염 바이러스에 대한 개별화된 치료

저자 : 진영주 ( Young-joo Jin )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 19-19 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

4A형, D형 및 E형간염 바이러스 감염의 최신지견

저자 : 이세환 ( Sae Hwan Lee )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 20-24 (5 pages)

다운로드

(기관인증 필요)

초록보기

Hepatitis A virus (HAV) is transmitted through fecal-oral infection, and acute hepatitis A infection has been continuously occurring in Korea since the 2000s. Despite ongoing medical and national health policy efforts for the prevention and treatment of acute hepatitis A, sporadic large-scale outbreaks were reported until today. Hepatitis E virus (HEV) is also transmitted by fecal-oral infection and the incidence of acute hepatitis E is not high in Korea, but it is one of the causes of acute hepatitis. In the case of hepatitis D virus (HDV) infection, there are still many limitations in diagnosis and treatment in worldwide.

5COVID-19의 역학과 SARS-CoV-2 바이러스의 특성

저자 : 최원석 ( Won-suk Choi )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 27-30 (4 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Since COVID-19 cases were reported in China in December 2019, the global COVID-19 pandemic continues. Initially, the known information about COVID-19 was very limited, but recently, various research results on epidemiological and viral characteristics have been reported. With increasing understanding of the disease, various medical and public health measures have been made and applied. In this lecture, the epidemiological characteristics of COVID-19 and the characteristics of SARS-CoV-2 that have been identified so far will be covered.

6COVID-19 상황에서 간질환 환자의 진료 가이던스

저자 : 이정훈 ( Jeong-hoon Lee )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 31-44 (14 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

7COVID-19과 간질환과의 연관

저자 : 정우진 ( Woo Jin Chung )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 45-49 (5 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Coronavirus disease 2019 (COVID-19) pandemics affected many aspects of the socioeconomic structure in Korea, especially in medical practice. As a major route of infection, the respiratory system is a key organ leading to increased risk of mortality and morbidity. However, it is well known that extra-respiratory involvement of COVID-19 also significantly affects patients' outcomes. Patients with chronic liver disease are not at increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). But, the risk of severe courses of COVID-19 may be different depending on the nature of the chronic liver disease and the presence of advanced fibrosis or cirrhosis. The present topic will summarize current evidences on the risk of infection and severe COVID-19 courses in patients with variable liver diseases.

8The Challenges and Achievements in COVID-19 Treatment and Vaccines

저자 : Pyoeng Gyun Choe

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 50-53 (4 pages)

다운로드

(기관인증 필요)

초록보기

In December 2019, a new strain of betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that cause coronavirus disease 2019 (COVID-19), emerged in Wuhan, China. Subsequently, the virus quickly spread worldwide, and the World Health Organization declared COVID-19 as a global pandemic on March 11, 2020. In response to the pandemic, many researchers are rushing to repurpose existing drugs to alter the course of severe COVID-19, as well as testing experimental treatments. Among antiviral agents, remdesivir, RNA-dependent RNA polymerase inhibitor, showed clinical benefit from randomized clinical trial. In October 2020, the FDA approved remdesivir for treating hospitalized patients with COVID-19, making it the first drug approved for COVID-19 treatment. The race to produce safe and effective vaccines is also moving at unprecedent speed. In December 2020, the FDA issued an emergency authorization use for the first vaccine for COVID-19.

9알코올 간질환 환자에서 고위험 환자의 선별

저자 : 송도선 ( Do Seon Song )

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 57-62 (6 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

Alcoholic liver disease includes steatosis, steatohepatitis, progressive fibrosis, and cirrhosis. Alcoholic hepatitis (AH) is an acute inflammatory syndrome characterized by rapid development of jaundice and liver-related complications, and it is associated, particularly if severe, with high mortality. Several prognostic models using laboratory or histologic markers have been used to estimate short-term mortality and to identify those who may benefit from treatment. Recently, prognostic models for acute-on-chronic liver failure were used in patients with severe AH, and systemic inflammatory markers and markers for hepatic injury were also studied for identifying high risk patients. Further studies to find models which can predict prognosis more accurately are needed in the future.

10How to Predict Rapid Progression of Fibrosis in Nonalcoholic Fatty Liver Disease

저자 : Byoung Kuk Jang

발행기관 : 대한간학회 간행물 : Postgraduate Courses (PG) 2021권 1호 발행 연도 : 2021 페이지 : pp. 63-63 (1 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기
12
발행기관 최신논문
자료제공: 네이버학술정보
발행기관 최신논문
자료제공: 네이버학술정보

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기